Lv3
246 积分 2021-11-04 加入
Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapies
1个月前
已完结
Phase I Trial of P-PSMA-101 CAR T Cells in Patients with Metastatic Castration-Resistant Prostate Cancer
2个月前
已完结
Effects of splenomegaly and splenic macrophage activity in hypersplenism due to cirrhosis
7个月前
已完结
Tonic signaling in CAR-T therapy: the lever long enough to move the planet
8个月前
已完结
Targeting the poliovirus receptor to activate T cells and induce myeloid-derived suppressor cells to differentiate to pro-inflammatory macrophages via the IFN-γ-p-STAT1-IRF8 axis in cancer therapy
9个月前
已完结
Analysis of CAR-Mediated Tonic Signaling
9个月前
已完结
Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies
9个月前
已完结
Pooled CAR-T screening in nonhuman primates identifies designs with enhanced proliferation, trafficking, and persistence
9个月前
已完结
Calibrating Chimeric Antigen Receptor (CAR) Signaling to Improve CAR T-Cell Therapies
11个月前
已完结
皖公网安备34019202002308
